These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32959073)

  • 1. Understanding Fibrosis in Systemic Sclerosis: Novel and Emerging Treatment Approaches.
    Yin H; Li R; Lu L; Yan Q
    Curr Rheumatol Rep; 2020 Sep; 22(11):77. PubMed ID: 32959073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting.
    van der Kroef M; Castellucci M; Mokry M; Cossu M; Garonzi M; Bossini-Castillo LM; Chouri E; Wichers CGK; Beretta L; Trombetta E; Silva-Cardoso S; Vazirpanah N; Carvalheiro T; Angiolilli C; Bekker CPJ; Affandi AJ; Reedquist KA; Bonte-Mineur F; Zirkzee EJM; Bazzoni F; Radstake TRDJ; Rossato M
    Ann Rheum Dis; 2019 Apr; 78(4):529-538. PubMed ID: 30793699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
    Luo Y; Wang Y; Shu Y; Lu Q; Xiao R
    Int J Biochem Cell Biol; 2015 Oct; 67():92-100. PubMed ID: 26043891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential.
    Tsou PS; Varga J; O'Reilly S
    Nat Rev Rheumatol; 2021 Oct; 17(10):596-607. PubMed ID: 34480165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic modulation as a therapy in systemic sclerosis.
    O'Reilly S
    Rheumatology (Oxford); 2019 Feb; 58(2):191-196. PubMed ID: 29579252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.
    Korman B
    Transl Res; 2019 Jul; 209():77-89. PubMed ID: 30876809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal models in systemic sclerosis: an update.
    Bi X; Mills T; Wu M
    Curr Opin Rheumatol; 2023 Nov; 35(6):364-370. PubMed ID: 37605874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic factors as drivers of fibrosis in systemic sclerosis.
    Bergmann C; Distler JH
    Epigenomics; 2017 Apr; 9(4):463-477. PubMed ID: 28343418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting fibrosis in systemic sclerosis.
    Lafyatis R
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):395-400. PubMed ID: 17214585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics, the holy grail in the pathogenesis of systemic sclerosis.
    Altorok N; Almeshal N; Wang Y; Kahaleh B
    Rheumatology (Oxford); 2015 Oct; 54(10):1759-70. PubMed ID: 24740406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the genetics and epigenetics of systemic sclerosis.
    Angiolilli C; Marut W; van der Kroef M; Chouri E; Reedquist KA; Radstake TRDJ
    Nat Rev Rheumatol; 2018 Nov; 14(11):657-673. PubMed ID: 30305700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives.
    Tsou PS
    Curr Rheumatol Rep; 2019 Dec; 21(12):69. PubMed ID: 31813068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis.
    Beyer C; Dees C; Distler JH
    Arch Dermatol Res; 2013 Jan; 305(1):1-8. PubMed ID: 23208311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target.
    Henderson J; Distler J; O'Reilly S
    Trends Mol Med; 2019 May; 25(5):395-411. PubMed ID: 30858032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetics and systemic sclerosis.
    Altorok N; Kahaleh B
    Semin Immunopathol; 2015 Sep; 37(5):453-62. PubMed ID: 26162437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetics and pathogenesis of systemic sclerosis; the ins and outs.
    Aslani S; Sobhani S; Gharibdoost F; Jamshidi A; Mahmoudi M
    Hum Immunol; 2018 Mar; 79(3):178-187. PubMed ID: 29330110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic approach to understanding the pathogenesis of systemic sclerosis.
    Zuo X; Zhang L; Luo H; Li Y; Zhu H
    Clin Genet; 2017 Oct; 92(4):365-371. PubMed ID: 27918067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network-based modeling of drug effects on disease module in systemic sclerosis.
    Kim KJ; Moon SJ; Park KS; Tagkopoulos I
    Sci Rep; 2020 Aug; 10(1):13393. PubMed ID: 32770109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.